India's Reliance Life Sciences brings first bevacizumab biosim to market

India street scene

Mumbai-based Reliance Life Sciences has launched a biosimilar of Roche's ($RHHBY) blockbuster cancer therapy bevacizumab (Avastin) in India--marking a first for the treatment that has been part of a legal tussle and off-label use concerns in the country.

The Drug Controller General of India had earlier approved a biosimilar of bevacizumab to treat colorectal cancer by the company. It will be marketed by Lupin under the name Bevacirel at a price level just shy of the original drug from Swiss-based Roche, according to the Economic Times.

The patented drug has multiple global cancer licenses, including for lung, kidney and ovarian tumors, and made over $6.6 billion last year--making it Roche's second-biggest seller in 2015. 


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

These sales are why the company has been fighting hard against copycats. In May, Roche filed a lawsuit to block approval of a biosimilar of the same drug by Hyderabad-based Hetero Drugs because of the use of language in the packaging label that draws on Roche's own work. 

In the case of bevacizumab, the Reliance version was not included in the lawsuit, but biosimilar approval standards in India are a sharp source of intellectual property contentions with multinational drug makers.

Reliance or Roche were not immediately available for comment.

According to the Economic Times, the price gap for the originator version is INR1,200 ($17.97) with the Roche price at INR29,500 for 100mg injection, compared to INR28,300 for the Reliance version.

Earlier this year, off-label use of Avastin in India to treat age-related macular degeneration was linked to partial loss of sight for 15 patients. Roche halted sales during the incident and warned against such use. Sales have since resumed.

- here's the story from the Economic Times

Related Articles:
Roche presses on biosimilar labels in India with Avastin challenge
Quality issues not behind sight loss in off-label Avastin use in India
Roche details hit to Avastin price in Japan


Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.